vTv Therapeutics to Present Two Posters at the American Diabetes Association’s 77th Scientific Sessions
June 08 2017 - 4:30PM
Business Wire
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage
biopharmaceutical company engaged in the discovery and development
of new orally administered treatments for Alzheimer’s disease,
diabetes and other therapeutic areas, today announced that Company
management will present two posters featuring vTv Therapeutics’
orally administered, non-peptide GLP-1R agonist at the American
Diabetes Association’s 77th Scientific Sessions held in San Diego,
California, June 9 – 13, 2017.
Details of the presentations are listed below:
Late-Breaking Poster title: “Is Less More? Learning to
Dose the Oral, Non-peptide GLP-1R Agonist, TTP273 in Type 2
Diabetics”Poster Number: 168-LBCategory: 12-E
Clinical Therapeutics/New Technology–Oral AgentsDate and
Time: Sunday, June 11, 2017, 12 - 1:00pm PTLocation:
Hall B
Poster title: “TTP273, Oral (Non-peptide) GLP-1R Agonist:
Improved Glycemic Control without Nausea and Vomiting in Phase
2”Poster number: 1220-PCategory: 12-E Clinical
Therapeutics/New Technology–Oral AgentsDate and Time:
Sunday, June 11, 2017, 12 - 1:00pm PTLocation: Hall B
“We look forward to providing an update on TTP273, one of vTv’s
lead diabetes compounds, at the American Diabetes Association’s
77th Scientific Sessions,” said Carmen Valcarce, Ph.D., executive
vice president, chief scientific officer, vTv Therapeutics. “We
remain focused on our goal of bringing forward both TTP273 and
TTP399, vTv’s glucokinase activator, and continue to pursue
opportunities with potential partners, including companies
based outside the U.S. We are confident that we will find the
right partner to support the continued development of these
investigational therapies, which we believe could offer new options
to patients with this disease.”
About TTP273
TTP273 is an investigational, orally dosed small molecule that
works by activating the GLP-1 receptor. Activation of the GLP-1
receptor leads to the enhancement of insulin secretion and
suppression of glucagon production and decreased food intake. There
are currently several marketed injectable GLP-1 therapies. These
agents have demonstrated notable glucose lowering in addition to
weight loss; however, their widespread use may be hindered by the
route of administration (injection) and by the high incidence of
gastrointestinal side effects (nausea and vomiting).
About Type 2 Diabetes
Type 2 diabetes is a result of the body’s inability to use
insulin properly to control sugar in the bloodstream. Type 2
diabetes represents up to 95% of diabetes patients, imposing a
growing burden on healthcare systems globally. Diabetes remains the
7th leading cause of death in the United States, costing the
healthcare system $245 billion annually. According to the American
Diabetes Association, there are 29.1 million Americans, or 9.3% of
the population, living with diabetes.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and Type 2
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions
and subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking
statements. These forward-looking statements represent our
estimates and assumptions only as of the date of this release and,
except as required by law, we undertake no obligation to update or
review publicly any forward-looking statements, whether as a result
of new information, future events or otherwise after the date of
this release. We anticipate that subsequent events and developments
will cause our views to change. Our forward-looking statements do
not reflect the potential impact of any future acquisitions,
merger, dispositions, joint ventures or investments we may
undertake. We qualify all of our forward-looking statements by
these cautionary statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170608006031/en/
Investors:vTv Therapeutics Inc.Michael Gibralter,
646-378-2938IR@vtvtherapeutics.comorMedia:Pure Communications
Inc.Katie Engleman, 910-509-3977Katie@purecommunicationsinc.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024